The revisions introduced in the recently published 24th EML and 10th EMLc will help to increase equitable access to safer and more effective therapies for people with bleeding disorders worldwide. The critical changes include adding emicizumab and recombinant FVIII and FIX concentrates to the core list, and elevating plasma-derived FVIII and FIX concentrates as well as desmopressin from the complementary to the core list. Also, pathogen-reduced and non-pathogen reduced cryoprecipitate have been removed as treatment options for hemophilia and VWD, while Factor IX Complex (PCC) was deleted from the list as a therapeutic alternative to FIX concentrates. Read the full article on all the changes, “WFH mobilizes global community to achieve milestone revisions to WHO EML” by clicking here.
To watch the panel discussion, click on the video below or click here to see it on the WFH eLearning Platform. The panel chaired by David Page, Consultant, Safety and Supply of Coagulation Products, Canadian Hemophilia Society and WFH Coagulation Product Safety, Supply and Access (CPSSA) Committee Member, includes the following speakers (in order of their seating in the video, left to right): Alain Baumann, CEO, WFH; Glenn Pierce, MD, PhD, WFH Vice President, Medical; Salome Mekhuzla, Director, Global Development, WFH; Radek Kaczmarek, Chair of the Coagulation Product Safety, Supply and Access (CPSSA) Committee, WFH; Mark W. Skinner, Board Member, WFH USA; Maria Elisa Mancuso, MD; Brian O’Mahony, Chief Executive, Irish Haemophilia Society; and Cesar Garrido, President, WFH.










